secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001437749-24-020590
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest
-----------------------------------------------------------------------

- New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.
- Interest rate reduced ~350 bps, saving ~$1.3M over loan life; maturity extended to June 2028.
- Revolving credit facility extended to June 2028 with max borrowing capacity increased to $14.5M.
- Received $3.5M from exercise of 2.17M warrants at $1.59; $2M used to pay down term loan.
- Shares outstanding 5,972,327 as of June 18, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/0001437749-24-020590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924020590/aytu20240607c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-020590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer